Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Board Meeting Outcome for Outcome Of Board Meeting Held On 1St August,2022

 We wish to inform you that the Board of Directors of Fredun Pharmaceuticals Limited (hereinafter referred to as 'the Company'), at their Meeting held on Monday, 01st August, 2022 at 11:00 am had considered and approved the following items of Business: 1. Availing Financial assistance from State Bank of India by acceptance of Sanction Letter received from the Bank. The Meeting of the Board Commenced at 11:00 A.M. and concluded at 11:30 A.M Kindly take the aforesaid information on your Records.
01-08-2022
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 In compliance to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018; we furnish hereunder the confirmation certificate received from the SEBI Registered Share Transfer Agent viz. Purva Sharegistry (India) Pvt. Ltd. for the quarter ended June 30, 2022. Kindly take the same on your Records.
01-08-2022
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Revised Financial Results For The Board Meeting Held On 16Th May, 2022

 Pursuant to Regulation 30 and 33 of SEBI (LODR) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held on 16.05.2022 at 03.00 p.m. considered, adopted and approved following items of business: 1. The Standalone Audited Financial Results for the Quarter and Financial Year ended 31.03.2022 along with Statement of Assets and Liabilities and cash flow statement as on that date. a. A copy of the said Financial Results along with the Auditor''s Report thereon; b. Declaration of unmodified opinion on the Standalone Financial Results as per Regulation 33 of SEBI (LODR) Regulations, 2015. 2. The Audited Standalone Financial Statements for the Financial Year ended March 31, 2022. 3. Recommended Final Dividend at 7% per Equity Share having face value of Rs. 10/- each for the Financial Year 2021-22; subject to the approval of the shareholders at the ensuing AGM of the Company
29-07-2022
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Closure of Trading Window

 Dear Sir / Madam, Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, and 'Code of Conduct for Prevention of Insider Trading' of Fredun Pharmaceuticals Limited (hereinafter referred to as the Company), the trading window for dealing in securities of the Company will remain closed for designated persons and their immediate relatives with effect from Thursday, 1st July, 2022 till 48 hours after the end of the Board Meeting wherein; the approval of Un-audited Financial Results for the quarter ended 30th June, 2022, would be considered, approved and declared. The said information is being notified to all designated persons under the above Regulations. Kindly take the same on your Records.
30-06-2022
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Allotment

 This is to inform you that Board of the Directors of the Company had pursuant to the approval of Shareholders in their Extraordinary General Meeting held on October 19, 2021 and allotment of convertible warrants on Preferential Basis to Non-Promoters was done on June 10, 2022. Further, we would like to inform that the Warrant Holders have paid the balance 75% of the consideration aggregating to Rs.63,75,149/- and have applied for exercising their rights for conversion of 20,136 warrants into equivalent number of Equity Shares. Consequently, the Board of Directors in its meeting held today i.e. June 10, 2022 has allotted 20,136 Equity Shares of face value Rs. 10/- each to the warrant holders. The allotment of the equity shares shall be made in dematerialized form and the equity shares so allotted shall rank pari passu with the existing Equity Shares of the Company in all respects. Kindly take the aforesaid information on your records.
10-06-2022
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Non Applicability Of Annual Secretarial Compliance Report For The Year Ended 31St March. 2022

 This is to inform you that the requirement of filing the Annual Secretarial Compliance Report as specified under Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with BSE Circulars dated 9th May, 2019, 3151 March 2022 and SEBI Circular No. CIR/CFD/CMDl/27 /2019 dated 8th February, 2019 is not applicable to our Company. With regard to same, we would like to draw your kind attention that the paid-up equity share capital of the company does not exceed rupees Ten Crore and Net Worth does not exceed rupees Twenty-Five Crore hence, as per the exemption provided under Regulation 15(2)(a) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, at present the requirement of submission of Annual Secretarial Compliance Report is not applicable to the Company. Kindly take the same on your Records.
27-05-2022
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Non Applicability Of Annual Secretarial Compliance Report For The Year Ended 31St March. 2022

 As per Regulation 15(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Corporate Governance provisions shall not apply to listed entities having paid-up equity share capital not exceeding rupees 10 Crores and net worth not exceeding rupees 25 Crores, as on the last day of previous financial year. With regard to same, we would like to draw your kind attention that the paid-up equity share capital of the company does not exceed rupees Ten Crore and Net Worth does not exceed rupees Twenty-Five Crore hence, as per the exemption provided under Regulation 15(2)(a) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, at present the requirement of submission of Annual Secretarial Compliance Report is not applicable to the Company. Kindly take the same on your Records.
27-05-2022
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Non-Applicability Of Regulation 23 (9) Of SEBI (LODR) Regulations, 2015 Regarding Submission Of Disclosures Of Related Party Transactions For The Year Ended 31St March. 2022

 This is to certify that in order to comply with Regulation 23 (9) SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 15 of Chapter IV SEBI (Listing Obligations Disclosure Requirements) Regulations, 2015 the paid up equity share capital does not exceed Rs. 10 crores and the Net-worth does not exceed Rs. 25 crores as on the last day of the previous financial year i.e. 31st March, 2022. With regard to same, we would like to draw your kind attention that the paid up equity share capital of the company does not exceed rupees Ten Crore and Net Worth does not exceed rupees Twenty Five Crore. Therefore, our Company is not required to submit disclosures for related party transactions for the half year /year ended on 31st March, 2022.
27-05-2022
Bigul

Fredun Pharmaceuticals Ltd - 539730 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

 This is to inform you that pursuant to Regulation 30(6) of the SEBI (Listing and Disclosure Requirements), 2015, the Analyst Meet was held through Video Conference on May 19, 2022 at 06:30 P.M. via Zoom with CA Ashutosh Agrawal from NB India Private Limited. The discussion was mainly about the ordinary course of business of the Company and about the industry and was not involving any Unpublished Price Sensitive Information (UPSI) Kindly take the same on your Records.
20-05-2022
Bigul

Annual report for Fredun Pharmaceuticals Ltd. for FY-2022
17-05-2022
Next Page
Close

Let's Open Free Demat Account